AVN 63.69 Decreased By ▼ -4.01 (-5.92%)
BOP 8.78 Decreased By ▼ -0.46 (-4.98%)
CHCC 134.50 Decreased By ▼ -3.50 (-2.54%)
DCL 10.05 Decreased By ▼ -0.53 (-5.01%)
DGKC 108.00 Decreased By ▼ -4.60 (-4.09%)
EFERT 64.45 Decreased By ▼ -0.35 (-0.54%)
EPCL 41.30 Decreased By ▼ -2.45 (-5.6%)
FCCL 21.00 Decreased By ▼ -0.26 (-1.22%)
FFL 15.05 Decreased By ▼ -0.76 (-4.81%)
HASCOL 15.08 Decreased By ▼ -0.62 (-3.95%)
HBL 131.10 Decreased By ▼ -3.90 (-2.89%)
HUBC 81.62 Decreased By ▼ -2.58 (-3.06%)
HUMNL 7.40 Decreased By ▼ -0.51 (-6.45%)
JSCL 24.29 Decreased By ▼ -1.81 (-6.93%)
KAPCO 28.35 Decreased By ▼ -0.79 (-2.71%)
KEL 3.71 Decreased By ▼ -0.12 (-3.13%)
LOTCHEM 11.75 Decreased By ▼ -0.24 (-2%)
MLCF 41.85 Decreased By ▼ -0.46 (-1.09%)
OGDC 93.33 Decreased By ▼ -3.02 (-3.13%)
PAEL 32.92 Decreased By ▼ -1.48 (-4.3%)
PIBTL 12.86 Decreased By ▼ -0.48 (-3.6%)
PIOC 95.00 Decreased By ▼ -4.00 (-4.04%)
POWER 9.77 Decreased By ▼ -0.30 (-2.98%)
PPL 83.60 Decreased By ▼ -2.36 (-2.75%)
PSO 200.00 Decreased By ▼ -6.89 (-3.33%)
SNGP 56.60 Decreased By ▼ -2.94 (-4.94%)
STPL 13.15 Decreased By ▼ -0.05 (-0.38%)
TRG 46.60 Decreased By ▼ -3.13 (-6.29%)
UNITY 23.00 Increased By ▲ 0.76 (3.42%)
WTL 1.05 Decreased By ▼ -0.02 (-1.87%)
BR100 4,159 Decreased By ▼ -129.49 (-3.02%)
BR30 21,156 Decreased By ▼ -721.9 (-3.3%)
KSE100 40,043 Decreased By ▼ -1144.33 (-2.78%)
KSE30 16,824 Decreased By ▼ -473.11 (-2.74%)
COVID-19 TOTAL DAILY
Business

Lilly's rheumatoid arthritis drug cuts COVID-19 deaths in trial

  • Lilly said the effect was most pronounced in patients on oxygen therapy, according to data from a US government-backed trial.
  • Lilly said 5.1% of patients on the drug combination died after 29 days versus 7.8% patients given remdesivir,
09 Oct 2020

Eli Lilly and Co said on Thursday fewer deaths were reported among COVID-19 patients taking a combination of its rheumatoid arthritis drug and Gilead Sciences Inc's remdesivir in a clinical trial, compared to only remdesivir.

Lilly said the effect was most pronounced in patients on oxygen therapy, according to data from a US government-backed trial, which however, was not designed to measure the effectiveness of baricitinib in preventing death.

In-line with data disclosed in September, the combination helped shorten the median recovery time by one day compared to remdesivir, meeting the study's main goal.

Lilly said 5.1% of patients on the drug combination died after 29 days versus 7.8% patients given remdesivir, which is already authorized in the US for treating COVID-19 patients, and a placebo.

Baricitinib, licensed by Lilly from Incyte Corp and approved to treat rheumatoid arthritis in the United States, could help suppress a potentially lethal immune response to COVID-19 called "cytokine storm".

Lilly said it was in talks with the US Food and Drug Administration to gain emergency use authorization for treating COVID-19 patients.